Login to Your Account

Exelixis, GSK Enter Deal With $134M Guarantee, Huge Potential

By Brady Huggett

Wednesday, October 30, 2002
When Exelixis Inc. was younger, it described itself as a model systems genetics and comparative genomics company. But a deal rich with up-front and potential funding disclosed after the markets closed Monday showed it has successfully made the move into drugs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription